Noravax's VLP Vaccine Closer To IND Filing

Noravax, Inc. (NASDAQ: NVAX) announced positive results from pre-clinical safety studies of its virus-like particle (VLP) vaccine for respiratory syncytial virus (RSV). In the animal model, the vaccine was effective and well-tolerated, according to McNicoll, Lewis & Vlak.

Three intramuscular injections were administered to rabbits with the RSV vaccine two weeks apart, and Noravax stated that there were no vaccine-related adverse effects, only mild and temporary reactions to the injection site were observed.

MLV maintains its "buy" rating and price target of $11.

Noravax, Inc. closed yesterday at $2.19.

See 4 Strong Buys here for free.